Cargando…
Comparison of AstraZeneca and sinopharm vaccines as boosters in protection against COVID-19 infection
BACKGROUND: As the global number of confirmed cases rises past 640 million, vaccination remains the most effective measure in controlling COVID-19. Studies have shown that two doses of vaccination can significantly reduce hospitalization and mortality rates among patients, but the effectiveness of b...
Autores principales: | Letafati, Arash, Eyvazzadeh, Nooshin, Gharehkhani, Amirhossein, Khorshidian, Ayeh, Chalabiani, Siavash, Soufiani, Elnaz Khodadoust, Khakpoor, Niloofar, Shamsodini, Benyamin, Beheshti, Taranom, Bavili Olyaei, Raha Taheri, Soleimani, Anahita, Melyani, Fatemeh, Hossein, Ghazal Mashhadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Alliance for Biological Standardization. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008804/ https://www.ncbi.nlm.nih.gov/pubmed/37004277 http://dx.doi.org/10.1016/j.biologicals.2023.101668 |
Ejemplares similares
-
A Battle against COVID-19: Vaccine Hesitancy and Awareness with a Comparative Study between Sinopharm and AstraZeneca
por: Boshra, Marian S., et al.
Publicado: (2022) -
Comparison of side effects of the dose-1 of AstraZeneca and Sinopharm vaccines in patients with multiple sclerosis in Kermanshah, Iran (2021)
por: Razazian, Nazanin, et al.
Publicado: (2023) -
Knowledge, Attitude, and Acceptance of Sinopharm and AstraZeneca’s COVID-19 Vaccines among Egyptian Population: A Cross-Sectional Study
por: Boshra, Marian S., et al.
Publicado: (2022) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021) -
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)